Marcus Unterrainer1,2, D F Fleischmann2,3, C Diekmann1, L Vomacka1, S Lindner1, F Vettermann1, M Brendel1, V Wenter1, B Ertl-Wagner4, J Herms5, C Wetzel6, R Rupprecht6, J C Tonn2,7, C Belka2,3, P Bartenstein1,2, M Niyazi2,3, Nathalie L Albert8,9. 1. Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 2. German Cancer Consortium (DKTK), Partner Site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany. 3. Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 4. Institute of Clinical Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 5. Department of Neuropathology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 6. Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany. 7. Department of Neurosurgery, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 8. Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. nathalie.albert@med.uni-muenchen.de. 9. German Cancer Consortium (DKTK), Partner Site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany. nathalie.albert@med.uni-muenchen.de.
Abstract
BACKGROUND: PET represents a valuable tool for glioma imaging. In addition to amino acid tracers such as 18F-FET, PET targeting the 18-kDa mitochondrial translocator-protein (TSPO) is of high interest for high-grade glioma (HGG) imaging due to its upregulation in HGG cells. 18F-GE-180, a novel TSPO ligand, has shown a high target-to-background contrast in HGG. Therefore, we intra-individually compared its uptake characteristics to dynamic 18F-FET PET and contrast-enhanced MRI in patients with HGG. METHODS: Twenty HGG patients (nine IDH-wildtype, 11 IDH-mutant) at initial diagnosis (n = 8) or recurrence (n = 12) were consecutively included and underwent 18F-GE-180 PET, dynamic 18F-FET PET, and MRI. The maximal tumour-to-background ratios (TBRmax) and biological tumour volumes (BTV) were evaluated in 18F-GE-180 and 18F-FET PET. Dynamic 18F-FET PET analysis included the evaluation of minimal time-to-peak (TTPmin). In MRI, the volume of contrast-enhancement was delineated (VOLCE). Volumes were spatially correlated using the Sørensen-Dice coefficient. RESULTS: The median TBRmax tended to be higher in 18F-GE-180 PET compared to 18F-FET PET [4.58 (2.33-8.95) vs 3.89 (1.56-7.15); p = 0.062] in the overall group. In subgroup analyses, IDH-wildtype gliomas showed a significantly higher median TBRmax in 18F-GE-180 PET compared to 18F-FET PET [5.45 (2.56-8.95) vs 4.06 (1.56-4.48); p = 0.008]; by contrast, no significant difference was observed in IDH-mutant gliomas [3.97 (2.33-6.81) vs 3.79 (2.01-7.15) p = 1.000]. Only 5/20 cases showed higher TBRmax in 18F-FET PET compared to 18F-GE-180 PET, all of them being IDH-mutant gliomas. No parameter in 18F-GE-180 PET correlated with TTPmin (p > 0.05 each). There was a tendency towards higher median BTVGE-180 [32.1 (0.4-236.0) ml] compared to BTVFET [19.3 (0.7-150.2) ml; p = 0.062] with a moderate spatial overlap [median Sørensen-Dice coefficient 0.55 (0.07-0.85)]. In MRI, median VOLCE [9.7 (0.1-72.5) ml] was significantly smaller than both BTVFET and BTVGE180 (p < 0.001 each), leading to a poor spatial correlation with BTVGE-180 [0.29 (0.01-0.48)] and BTVFET [0.38 (0.01-0.68)]. CONCLUSION: PET with 18F-GE-180 and 18F-FET provides differing imaging information in HGG dependent on the IDH-mutational status, with diverging spatial overlap and vast exceedance of contrast-enhancement in MRI. Combined PET imaging might reveal new insights regarding non-invasive characterization of tumour heterogeneity and might influence patients' management.
BACKGROUND: PET represents a valuable tool for glioma imaging. In addition to amino acid tracers such as 18F-FET, PET targeting the 18-kDa mitochondrial translocator-protein (TSPO) is of high interest for high-grade glioma (HGG) imaging due to its upregulation in HGG cells. 18F-GE-180, a novel TSPO ligand, has shown a high target-to-background contrast in HGG. Therefore, we intra-individually compared its uptake characteristics to dynamic 18F-FET PET and contrast-enhanced MRI in patients with HGG. METHODS: Twenty HGG patients (nine IDH-wildtype, 11 IDH-mutant) at initial diagnosis (n = 8) or recurrence (n = 12) were consecutively included and underwent 18F-GE-180 PET, dynamic 18F-FET PET, and MRI. The maximal tumour-to-background ratios (TBRmax) and biological tumour volumes (BTV) were evaluated in 18F-GE-180 and 18F-FET PET. Dynamic 18F-FET PET analysis included the evaluation of minimal time-to-peak (TTPmin). In MRI, the volume of contrast-enhancement was delineated (VOLCE). Volumes were spatially correlated using the Sørensen-Dice coefficient. RESULTS: The median TBRmax tended to be higher in 18F-GE-180 PET compared to 18F-FET PET [4.58 (2.33-8.95) vs 3.89 (1.56-7.15); p = 0.062] in the overall group. In subgroup analyses, IDH-wildtype gliomas showed a significantly higher median TBRmax in 18F-GE-180 PET compared to 18F-FET PET [5.45 (2.56-8.95) vs 4.06 (1.56-4.48); p = 0.008]; by contrast, no significant difference was observed in IDH-mutant gliomas [3.97 (2.33-6.81) vs 3.79 (2.01-7.15) p = 1.000]. Only 5/20 cases showed higher TBRmax in 18F-FET PET compared to 18F-GE-180 PET, all of them being IDH-mutant gliomas. No parameter in 18F-GE-180 PET correlated with TTPmin (p > 0.05 each). There was a tendency towards higher median BTVGE-180 [32.1 (0.4-236.0) ml] compared to BTVFET [19.3 (0.7-150.2) ml; p = 0.062] with a moderate spatial overlap [median Sørensen-Dice coefficient 0.55 (0.07-0.85)]. In MRI, median VOLCE [9.7 (0.1-72.5) ml] was significantly smaller than both BTVFET and BTVGE180 (p < 0.001 each), leading to a poor spatial correlation with BTVGE-180 [0.29 (0.01-0.48)] and BTVFET [0.38 (0.01-0.68)]. CONCLUSION: PET with 18F-GE-180 and 18F-FET provides differing imaging information in HGG dependent on the IDH-mutational status, with diverging spatial overlap and vast exceedance of contrast-enhancement in MRI. Combined PET imaging might reveal new insights regarding non-invasive characterization of tumour heterogeneity and might influence patients' management.
Authors: Nathalie L Albert; M Unterrainer; D F Fleischmann; S Lindner; F Vettermann; A Brunegraf; L Vomacka; M Brendel; V Wenter; C Wetzel; R Rupprecht; J-C Tonn; C Belka; P Bartenstein; M Niyazi Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-19 Impact factor: 9.236
Authors: Per Jensen; Ling Feng; Ian Law; Claus Svarer; Gitte M Knudsen; Jens D Mikkelsen; Robin de Nijs; Vibeke A Larsen; Agnete Dyssegaard; Gerda Thomsen; Walter Fischer; Denis Guilloteau; Lars H Pinborg Journal: J Nucl Med Date: 2015-07-16 Impact factor: 10.057
Authors: Sabina Eigenbrod; Raimund Trabold; David Brucker; Christian Erös; Rupert Egensperger; Christian La Fougere; Werner Göbel; Adrian Rühm; Hans A Kretzschmar; Jörg C Tonn; Jochen Herms; Armin Giese; Friedrich W Kreth Journal: Acta Neurochir (Wien) Date: 2014-05-03 Impact factor: 2.216
Authors: Nathalie L Jansen; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Andrei Todica; Sabina Eigenbrod; Maximilian Niyazi; Jörg-Christian Tonn; Peter Bartenstein; Friedrich-Wilhelm Kreth; Christian la Fougère Journal: J Nucl Med Date: 2015-01 Impact factor: 10.057
Authors: Bogdana Suchorska; Nathalie L Jansen; Jennifer Linn; Hans Kretzschmar; Hendrik Janssen; Sabina Eigenbrod; Matthias Simon; Gabriele Pöpperl; Friedrich W Kreth; Christian la Fougere; Michael Weller; Joerg C Tonn Journal: Neurology Date: 2015-01-21 Impact factor: 9.910
Authors: Nathalie L Albert; Marcus Unterrainer; Matthias Brendel; Lena Kaiser; Markus Zweckstetter; Paul Cumming; Peter Bartenstein Journal: Eur J Nucl Med Mol Imaging Date: 2019-03-02 Impact factor: 9.236
Authors: Paolo Zanotti-Fregonara; Mattia Veronese; Belen Pascual; Robert C Rostomily; Federico Turkheimer; Joseph C Masdeu Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-17 Impact factor: 9.236
Authors: M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-05 Impact factor: 9.236
Authors: Lena Kaiser; Adrien Holzgreve; Stefanie Quach; Michael Ingrisch; Marcus Unterrainer; Franziska J Dekorsy; Simon Lindner; Viktoria Ruf; Julia Brosch-Lenz; Astrid Delker; Guido Böning; Bogdana Suchorska; Maximilian Niyazi; Christian H Wetzel; Markus J Riemenschneider; Sophia Stöcklein; Matthias Brendel; Rainer Rupprecht; Niklas Thon; Louisa von Baumgarten; Jörg-Christian Tonn; Peter Bartenstein; Sibylle Ziegler; Nathalie L Albert Journal: Cancers (Basel) Date: 2021-12-23 Impact factor: 6.639
Authors: Bastian Zinnhardt; Michael Müther; Wolfgang Roll; Philipp Backhaus; Astrid Jeibmann; Claudia Foray; Cristina Barca; Christian Döring; Bertrand Tavitian; Frédéric Dollé; Matthias Weckesser; Alexandra Winkeler; Sven Hermann; Stefan Wagner; Heinz Wiendl; Walter Stummer; Andreas H Jacobs; Michael Schäfers; Oliver M Grauer Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300
Authors: Norbert Galldiks; Maximilian Niyazi; Anca L Grosu; Martin Kocher; Karl-Josef Langen; Ian Law; Giuseppe Minniti; Michelle M Kim; Christina Tsien; Frederic Dhermain; Riccardo Soffietti; Minesh P Mehta; Michael Weller; Jörg-Christian Tonn Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300
Authors: Franziska J Vettermann; Stefanie Harris; Julia Schmitt; Marcus Unterrainer; Simon Lindner; Boris-Stephan Rauchmann; Carla Palleis; Endy Weidinger; Leonie Beyer; Florian Eckenweber; Sebastian Schuster; Gloria Biechele; Christian Ferschmann; Vladimir M Milenkovic; Christian H Wetzel; Rainer Rupprecht; Daniel Janowitz; Katharina Buerger; Robert Perneczky; Günter U Höglinger; Johannes Levin; Christian Haass; Joerg C Tonn; Maximilian Niyazi; Peter Bartenstein; Nathalie L Albert; Matthias Brendel Journal: Life (Basel) Date: 2021-05-26